A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Android Lollipop was the 5.0 release of Google’s mobile operating system. This version of Android launched with groundbreaking features, including an all-new “Material Design” language ...